[go: up one dir, main page]

WO2000071169A3 - Magnetic resonance tracking of magnetically labeled cells - Google Patents

Magnetic resonance tracking of magnetically labeled cells Download PDF

Info

Publication number
WO2000071169A3
WO2000071169A3 PCT/US2000/013826 US0013826W WO0071169A3 WO 2000071169 A3 WO2000071169 A3 WO 2000071169A3 US 0013826 W US0013826 W US 0013826W WO 0071169 A3 WO0071169 A3 WO 0071169A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
magnetic resonance
sensitive
mri
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013826
Other languages
French (fr)
Other versions
WO2000071169A2 (en
Inventor
Jeff W Bulte
Ian D Duncan
Joseph A Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU51463/00A priority Critical patent/AU5146300A/en
Publication of WO2000071169A2 publication Critical patent/WO2000071169A2/en
Publication of WO2000071169A3 publication Critical patent/WO2000071169A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The method of the present invention is to label living cells so as to render them detectable in MRI. The invention relates to the use of magnetic resonance (MR) sensitive agents to render treated living cells identifiable and distinguishable in MR Imaging (MRI). MR sensitive agents can be bound to a targeting compound such as a protein or antibody. The targeting compound reacts with living cells in a way that the MR sensitive agent is incorporated into the or onto the cell surface. The MR sensitive agents can also be coated with agents that render the magnetic resonance sensitive agent able to bind to or be internalized by cells. The treated cells of the invention can be applied to patient for any therapeutic, diagnostic, or experimental purpose. The invention also encompasses imaging the host with MRI to locate MR labeled cells, to track their migration or bio-distribution non-invasively, and to establish to survival characteristics of such cells.
PCT/US2000/013826 1999-05-21 2000-05-19 Magnetic resonance tracking of magnetically labeled cells Ceased WO2000071169A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51463/00A AU5146300A (en) 1999-05-21 2000-05-19 Magnetic resonance tracking of magnetically labeled cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13542899P 1999-05-21 1999-05-21
US60/135,428 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000071169A2 WO2000071169A2 (en) 2000-11-30
WO2000071169A3 true WO2000071169A3 (en) 2001-08-02

Family

ID=22468067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013826 Ceased WO2000071169A2 (en) 1999-05-21 2000-05-19 Magnetic resonance tracking of magnetically labeled cells

Country Status (2)

Country Link
AU (1) AU5146300A (en)
WO (1) WO2000071169A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7971592B2 (en) 2003-06-30 2011-07-05 Eisai R&D Management Co., Ltd. Magnetic cell and method of using the same
US9265577B2 (en) 2007-05-18 2016-02-23 The Johns Hopkins University Methods and systems for providing planning and dispensation of research and/or treatment for brain disease

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713173B2 (en) 1996-11-16 2004-03-30 Nanomagnetics Limited Magnetizable device
US6986942B1 (en) 1996-11-16 2006-01-17 Nanomagnetics Limited Microwave absorbing structure
US6815063B1 (en) 1996-11-16 2004-11-09 Nanomagnetics, Ltd. Magnetic fluid
GB2319253A (en) 1996-11-16 1998-05-20 Eric Leigh Mayes Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles
EP1376443A1 (en) * 2002-06-19 2004-01-02 BrainLAB AG Method and device for determining the migration ways of cells
US8249813B2 (en) 2003-05-22 2012-08-21 Brainlab Ag System and process for metabolic guidance of introduced cellular material
US7848543B2 (en) 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
WO2005095621A1 (en) * 2004-03-31 2005-10-13 Genomidea Inc. Method of regulating gene introduction with use of artificial magnetic material and system therefor
DE102004052533A1 (en) † 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core
US8580230B2 (en) 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
DE102009060317B4 (en) * 2009-12-23 2013-04-04 Siemens Aktiengesellschaft A contrast agent for use in an imaging method for diagnosing a metastatic tumor disease and a method for imaging a metastatic tumor tissue
WO2011141766A1 (en) * 2010-05-11 2011-11-17 University Of Calcutta Ferritin biosensor and methods of using the same
CN113648426B (en) * 2021-08-18 2024-10-29 浙江大学 Construction method and application of magnetic nanoparticles capable of being connected in two directions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BULTE J W M ET AL: "DEXTRAN-MAGNETITE PARTICLES: CONTRAST-ENHANCED MRI OF BLOOD-BRAIN BARRIER DISRUPTION IN A RAT MODEL*", MAGNETIC RESONANCE IN MEDICINE,US,ACADEMIC PRESS, DULUTH, MN, vol. 23, no. 2, 1 February 1992 (1992-02-01), pages 215 - 223, XP000261759, ISSN: 0740-3194 *
BULTE J W M ET AL: "Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 194, no. 1-3, April 1999 (1999-04-01), pages 204 - 209, XP004166667, ISSN: 0304-8853 *
BULTE J W M ET AL: "Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran - magnetite particles", MAGNETIC RESONANCE IN MEDICINE,US,ACADEMIC PRESS, DULUTH, MN, vol. 25, no. 1, 1992, pages 148 - 157, XP002112218, ISSN: 0740-3194 *
BULTE J.W.M. ET AL: "Short-vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents", J. MAGNETIC RESONANCE IMAGING, vol. 9, February 1999 (1999-02-01), pages 329 - 335, XP000986439 *
BULTE J.W.M. ET AL: "Tagging of T cells with superparamagnetic iron oxide: Uptake kinetics and relaxometry", ACAD RADIOL., vol. 3, 3 August 1996 (1996-08-03), pages s301 - s303, XP000986426 *
BULTE, J. W. M. ET AL: "Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination", PNAS, vol. 96, no. 26, 21 December 1999 (1999-12-21), pages 15256 - 15261, XP000982063 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7971592B2 (en) 2003-06-30 2011-07-05 Eisai R&D Management Co., Ltd. Magnetic cell and method of using the same
US8701676B2 (en) 2003-06-30 2014-04-22 Eisai R&D Management Co. Ltd. Magnetic cell and method of using the same
US9265577B2 (en) 2007-05-18 2016-02-23 The Johns Hopkins University Methods and systems for providing planning and dispensation of research and/or treatment for brain disease

Also Published As

Publication number Publication date
WO2000071169A2 (en) 2000-11-30
AU5146300A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
WO2000071169A3 (en) Magnetic resonance tracking of magnetically labeled cells
Farzin et al. Magnetic nanoparticles in cancer therapy and diagnosis
Chen et al. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle
Li et al. A bioinspired nanoprobe with multilevel responsive T1‐weighted MR signal‐amplification illuminates ultrasmall metastases
Hawrylak et al. Nuclear magnetic resonance (NMR) imaging of iron oxide-labeled neural transplants
Adolphi et al. Imaging of Her2‐targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID‐detected magnetic relaxometry and MRI
Hilger et al. Towards breast cancer treatment by magnetic heating
Wabler et al. Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content
BRPI9910394A (en) scintigraphy-specific binding molecules and conjugates containing them
Groman et al. Ultrasmall mixed ferrite colloids as multidimensional magnetic resonance imaging, cell labeling, and cell sorting agents
Sharma et al. Gd nanoparticulates: from magnetic resonance imaging to neutron capture therapy
Barakat Magnetically modulated nanosystems: a unique drug-delivery platform
ATE99544T1 (en) LIPOSOMAL RADIOLOGICAL CONTRAST AGENT.
Caravan et al. Structure–relaxivity relationships among targeted MR contrast agents
AU8204787A (en) Detection of necrotic malignant tissue and associated therapy
NO930465D0 (en) UNSIDED COMPLEX COMPREHENSIVE WATER SOLUBLE CARBOXY POLYSACCARIDE MAGNETIC IRON OXYD
ES2130406T3 (en) MATERIAL COMPOSED OF SMALL DIAMETER COMPOSED OF CARBOXIPOLISACARIDO SOLUBLE IN WATER AND MAGNETIC IRON OXIDE.
Gao et al. Magnetic nanoparticles for biomedical applications: From diagnosis to treatment to regeneration
JP2002519440A5 (en)
Chertok et al. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers
TAUBER et al. The interaction of the high‐density lipoprotein with cultured cells of bovine vascular endothelium
Li et al. Enzyme‐triggered transforming of assembly peptide‐modified magnetic resonance‐tuned probe for highly sensitive imaging of bacterial infection in vivo
Bulte et al. Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats
CN101636108B (en) Imaging activated vascular endothelium with immunomagnetic MRI contrast agents
PL337287A1 (en) Application of intravenous contrast media in projection mammography

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09979464

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP